drugset / Trial / NCT00283829

Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

NCT00283829

Phase 1/2 Completed 30 enrolled University of Washington Sanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test if interleukin-2, a drug that stimulates the immune system, can be used after chemotherapy to slow the progression of your disease. We also want to test what the best dose of interleukin-2 is that can be used safely at home. Interleukin-2, abbreviated as IL2, is a naturally produced growth hormone for the immune cells in our body. It stimulates the growth of the immune cells and enhances their ability to fight infections and cancers. In people with cancer, the immune cells are typically suppressed and became even more so after irradiation and chemotherapy treatment. By giving you more IL2 we hope to enhance the immune system so that it can fight the cancer better, control cancer growth and shrink the cancer.

Timeline

Start
2002-09
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic Subcutaneous
Background Docetaxel Small molecule Intravenous

Indications